About CrossBridge Bio
CrossBridge Bio is a company based in Houston (United States) founded in 2023 was acquired by Lilly in April 2026. CrossBridge Bio has raised $10 million across 1 funding round from investors including Lilly, TMC Venture Fund and CE Ventures. CrossBridge Bio offers products and services including ADC Technology Platform, EGCit Linker, and Enzymatic Conjugation. CrossBridge Bio operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Dren Bio, among others.
- Headquarter Houston, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CrossBridge Bio
CrossBridge Bio offers a comprehensive portfolio of products and services, including ADC Technology Platform, EGCit Linker, and Enzymatic Conjugation.
Platform for creating stable Antibody-Drug Conjugates to target cancer cells effectively.
Enzymatically cleavable linker enhancing ADC stability and targeted payload release.
Technique for precise integration of multi-arm linkers in ADC production.
Funding Insights of CrossBridge Bio
CrossBridge Bio has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Seed round of $10 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CrossBridge Bio
CrossBridge Bio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, TMC Venture Fund and CE Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage Life-Sciences & Offline focused VC firm funding companies in the US
|
Locked | Locked | Locked | |
|
Stage-agnostic tech-focused VC firm investing in geographies such as Israel and China
|
Locked | Locked | Locked | |
|
Portal Innovations is engaged in funding life sciences startups.
|
Locked | Locked | Locked |
Investor details for CrossBridge Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CrossBridge Bio
Investment portfolio details for CrossBridge Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CrossBridge Bio
Detailed financials for CrossBridge Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Crossbridge Bio Comparisons
Peer comparison for CrossBridge Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CrossBridge Bio
CrossBridge Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Dren Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
Detailed competitors of CrossBridge Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Crossbridge Bio
Complete news archive for CrossBridge Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CrossBridge Bio
CrossBridge Bio was founded in 2023 and raised its 1st funding round 1 year after it was founded.
CrossBridge Bio is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
CrossBridge Bio is a funded company, having raised a total of $10M across 1 funding round to date.
CrossBridge Bio was founded in 2023 and is headquartered in Houston, United States. Antibody-Drug Conjugate therapeutics are developed within the biotechnology sector, with operations centered on a stable dual-linker payload technology. This technology supports various candidates, including the lead CB-120, which targets cancer treatment. Focus is placed on oncology applications through research and therapeutic development.
CrossBridge Bio's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
CrossBridge Bio offers ADC Technology Platform, EGCit Linker, and Enzymatic Conjugation.
CrossBridge Bio has 7 investors. Key investors include Lilly, TMC Venture Fund, CE Ventures, Crescent Enterprises, and Portal Innovations.